The insider cluster is too small to be informative, monitor for larger directional trades or a change in pattern. Focus on upcoming earnings or pipeline catalysts for real signals.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 4 $24.69entry
- T+1 · 3mo ago +1.74%α +1.94% · $25.12
- T+5 · 3mo ago +5.14%α +5.24% · $25.96
- T+20 · due 3mo ago Pending
- T+60 · due 20d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a combined $539K of stock in a 7-day window, representing only ~0.02% of the $2.4B market cap. The sales coincide with option exercises and appear to be routine liquidity/tax-related transactions, not a negative signal on the company's prospects.
Key Financial Metrics
Key Facts
- Total open-market sales: $539K (0.02% of $2.4B market cap)
- Insiders: CFO van Houte, CSO Hansen, CLO Ring, all C-suite
- Sales follow option exercises at $0 or $8.72 strike, consistent with tax withholding / diversification
- No insider buying in the cluster, all activity is sell-side
Financial Impact
Trivial, $539K in sales vs $2.4B market cap is immaterial
Risk Factors
- Routine insider selling does not predict stock movement; no bearish signal here
- Option exercises could lead to future dilution if insiders hold the shares, but sales are minimal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1785794472087 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers